Factor xa inhibitors
- 1 lab in 1 country
- 4 of 4 findings with company ties
- Humans1
Associations
4Mortality
downin humans1HR 0.41
1 study
Mortality
downin humans1HR 0.41
Factor xa inhibitors lower the risk of mortality in humans (HR 0.41, 95% CI 0.23-0.75).
“cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group (hazard ratio [95% confidence interval]: 0.43 [0.30-0.61], 0.44 [0.29-0.66], 0.47 [0.22-1.04], and 0.41 [0.23-0.75]”
Humansnonvalvular atrial fibrillation5-year
Aging10 Apr 2025
Atherosclerosis
downin humans1HR 0.47
1 study
Atherosclerosis
downin humans1HR 0.47
Factor xa inhibitors lower the risk of atherosclerosis in humans (HR 0.47, 95% CI 0.22-1.04).
“arteriosclerotic disease, and cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group (hazard ratio [95% confidence interval]: 0.43 [0.30-0.61], 0.44 [0.29-0.66], 0.47 [0.22-1.04]”
Humansnonvalvular atrial fibrillation5-year
Aging10 Apr 2025
Heart failure
downin humans1HR 0.44
1 study
Heart failure
downin humans1HR 0.44
Factor xa inhibitors lower the risk of heart failure in humans (HR 0.44, 95% CI 0.29-0.66).
“congestive heart failure, arteriosclerotic disease, and cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group (hazard ratio [95% confidence interval]: 0.43 [0.30-0.61], 0.44 [0.29-0.66]”
Humansnonvalvular atrial fibrillation5-year
Aging10 Apr 2025
Cardiovascular events
downin humans1HR 0.43
1 study
Cardiovascular events
downin humans1HR 0.43
Factor xa inhibitors lower the risk of cardiovascular events in humans (HR 0.43, 95% CI 0.30-0.61).
“The risks of cardiovascular events, congestive heart failure, arteriosclerotic disease, and cardiovascular death were significantly lower in the Xa-I group than in the non-Xa-I group”
Humansnonvalvular atrial fibrillation5-year
Aging10 Apr 2025